Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolent Health, Inc.EVH · Entity 5492 | Director | June 13, 2018 | June 15, 2018 |
| Progyny, Inc.PGNY · Entity 4521 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolent Health, Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 21,284 |
Reported balance
After 2018-06-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 5,459 · Balance 21,284 F1: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted to Dr. Payson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
F2: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date.
F3: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
Progyny, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,349 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 5,660 · Balance 12,349 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.69 · Expires 2036-05-20 | Direct | 3,203 |
Reported balance
After 2026-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-21 · Grant · Acquired 3,203 · Balance 3,203 F4: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.69 · Expires 2036-05-20 | Direct | 27,119 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Grant · Acquired 27,119 · Balance 27,119 F5: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 331,363 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 331,363 F2: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 122,493 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 122,493 F3: The reportable securities are directly held by EVO Eagle, LLC. The Reporting Person shares voting and dispositive power over the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
F2: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust.
F3: The reportable securities are directly held by EVO Eagle, LLC. The Reporting Person shares voting and dispositive power over the securities.
F4: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
F5: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apria, Inc.
Report date March 29, 2022 · Filed March 29, 2022
Section 16 reporting ended · disclosed 2022-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-29 · Disposition to issuer · Disposed 5,059 · Balance 0 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee.
F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.
F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:21 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 27,119 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001551306-26-000097 · wk-form4_1779826910.xml · derivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,119 Underlying: Common Stock · 27,119 shares Expires 2036-05-20 F5 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:21 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 3,203 | $12.49 Strike: $24.69 | $40,005.47 |
DisclosureSEC source: 0001551306-26-000097 · wk-form4_1779826910.xml · derivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,203 Underlying: Common Stock · 3,203 shares Expires 2036-05-20 F4 · price: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. F4 · derivative.exercise_date: The option was issued to the Reporting Person in lieu of an annual cash retainer of $39,990 for board and committee service. The shares subject to the option will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:21 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 5,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-26-000097 · wk-form4_1779826910.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,349 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on the earlier of (i) May 21, 2027 or (ii) the calendar day immediately preceding the date of the Issuer's first annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on such date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:48 UTC | Progyny, Inc. PGNY · Entity 4521 | GiftCommon Stock | 50,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-25-000199 · wk-form4_1763502525.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,689 F2 · shares: On November 18, 2025, the Reporting Person transferred 50,265 shares held directly by the Reporting Person to The Norman C. and Melinda B. Payson Revocable Trust for no consideration. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:48 UTC | Progyny, Inc. PGNY · Entity 4521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,224 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001551306-25-000199 · wk-form4_1763502525.xml · derivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,224 shares Expires 2026-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:48 UTC | Progyny, Inc. PGNY · Entity 4521 | Exercise / conversionCommon Stock | 36,224 | $1.45 | $52,524.80 |
DisclosureSEC source: 0001551306-25-000199 · wk-form4_1763502525.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person paid the exercise price for the option in cash and has held all shares received upon exercise. No shares of stock were sold in connection with this transaction. Read SEC document |
| May 22, 2025 Filed May 28, 2025 01:44 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 30,401 | $0.00 Strike: $20.89 | $0.00 |
DisclosureSEC source: 0001551306-25-000110 · wk-form4_1748396634.xml · derivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,401 Underlying: Common Stock · 30,401 shares Expires 2035-05-21 F4 · derivative.exercise_date: The shares subject to the option will vest on May 22, 2026, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 22, 2025 Filed May 28, 2025 01:44 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-25-000110 · wk-form4_1748396634.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,730 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 22, 2026, subject to the Reporting Person's continued service on such date. Read SEC document |
| November 23, 2024 Filed Nov 26, 2021 21:34 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 200 | $56.29 | $11,258.00 |
DisclosureSEC source: 0001179110-21-010417 · edgar.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 580,656 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 21, 2021. F3 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9) and (10). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.37, inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:43 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 24,140 | $0.00 Strike: $27.15 | $0.00 |
DisclosureSEC source: 0001551306-24-000118 · wk-form4_1716946996.xml · derivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,140 Underlying: Common Stock · 24,140 shares Expires 2034-05-22 F4 · derivative.exercise_date: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:43 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 6,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001551306-24-000118 · wk-form4_1716946996.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,041 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 17,670 | $0.00 Strike: $38.24 | $0.00 |
DisclosureSEC source: 0001628280-23-019980 · wf-form4_168513520867999.xml · derivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,670 Underlying: Common Stock · 17,670 shares Expires 2033-05-23 F4 · derivative.exercise_date: The shares subject to the Option shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 4,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-019980 · wf-form4_168513520867999.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,865 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 24, 2024, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:29 UTC | Progyny, Inc. PGNY · Entity 4521 | GiftCommon Stock | 8,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-004045 · wf-form4_167666931243488.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 281,098 F2 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:29 UTC | Progyny, Inc. PGNY · Entity 4521 | GiftCommon Stock | 8,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-004045 · wf-form4_167666931243488.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,480 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his trust, The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 21:22 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,617 | $30.89 | $204,399.13 |
DisclosureSEC source: 0001628280-22-032590 · wf-form4_167217616376591.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 272,446 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.35 to $31.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 21:59 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,617 | $31.65 | $209,428.05 |
DisclosureSEC source: 0001628280-22-032493 · wf-form4_167174632359756.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 279,063 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.34 to $32.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,017 | $32.70 | $196,755.90 |
DisclosureSEC source: 0001628280-22-031664 · wf-form4_167062002174536.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 285,680 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.38 to $33.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 600 | $31.86 | $19,116.00 |
DisclosureSEC source: 0001628280-22-031664 · wf-form4_167062002174536.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 291,697 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.35 to $32.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,022 | $32.10 | $64,906.20 |
DisclosureSEC source: 0001628280-22-031664 · wf-form4_167062002174536.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 292,297 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.66 to $32.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,295 | $31.23 | $71,672.85 |
DisclosureSEC source: 0001628280-22-031664 · wf-form4_167062002174536.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 294,319 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.65 to $31.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:07 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,300 | $30.08 | $69,184.00 |
DisclosureSEC source: 0001628280-22-031664 · wf-form4_167062002174536.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 296,614 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.65 to $30.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 21:20 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,617 | $34.25 | $226,632.25 |
DisclosureSEC source: 0001628280-22-030871 · wf-form4_166967032380637.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 298,914 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.90 to $34.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:10 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,617 | $33.80 | $223,654.60 |
DisclosureSEC source: 0001628280-22-030749 · wf-form4_166923780313579.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 305,531 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.40 to $34.235, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 100 | $39.84 | $3,984.00 |
DisclosureSEC source: 0001628280-22-029821 · wf-form4_166845969268321.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 312,148 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,900 | $38.96 | $74,024.00 |
DisclosureSEC source: 0001628280-22-029821 · wf-form4_166845969268321.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 312,248 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.60 to $39.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,617 | $37.79 | $174,476.43 |
DisclosureSEC source: 0001628280-22-029821 · wf-form4_166845969268321.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 314,148 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.525 to $38.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 900 | $39.55 | $35,595.00 |
DisclosureSEC source: 0001628280-22-029821 · wf-form4_166845969268321.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 318,765 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.13 to $39.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,300 | $38.58 | $50,154.00 |
DisclosureSEC source: 0001628280-22-029821 · wf-form4_166845969268321.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 319,665 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 21:03 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,417 | $37.54 | $165,814.18 |
DisclosureSEC source: 0001628280-22-029821 · wf-form4_166845969268321.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 320,965 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.03 to $37.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 20:37 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,717 | $41.43 | $236,855.31 |
DisclosureSEC source: 0001628280-22-027321 · wf-form4_166698944564190.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 325,382 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.20 to $41.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 20:37 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 900 | $40.68 | $36,612.00 |
DisclosureSEC source: 0001628280-22-027321 · wf-form4_166698944564190.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 331,099 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.18 to $41.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 20:37 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 400 | $42.52 | $17,008.00 |
DisclosureSEC source: 0001628280-22-027321 · wf-form4_166698944564190.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 331,999 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.375 to $42.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 20:37 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 2,333 | $41.98 | $97,939.34 |
DisclosureSEC source: 0001628280-22-027321 · wf-form4_166698944564190.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 332,399 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.36 to $42.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 20:37 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 3,884 | $41.08 | $159,554.72 |
DisclosureSEC source: 0001628280-22-027321 · wf-form4_166698944564190.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 334,732 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.36 to $41.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:48 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantStock Option (Right to Buy) · Derivative | 15,080 | $0.00 Strike: $38.22 | $0.00 |
DisclosureSEC source: 0001628280-22-027107 · wf-form4_166682085536140.xml · derivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,080 Underlying: Common Stock · 15,080 shares Expires 2032-10-23 F4 · derivative.exercise_date: The shares subject to the Option shall vest on May 23, 2023, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:48 UTC | Progyny, Inc. PGNY · Entity 4521 | GrantCommon Stock | 3,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-027107 · wf-form4_166682085536140.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,132 F1 · shares: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs shall vest on May 23, 2023 subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:18 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,287 | $39.00 | $167,193.00 |
DisclosureSEC source: 0001628280-22-026414 · wf-form4_166577869073110.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 338,616 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.62 to $39.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:18 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 630 | $38.33 | $24,147.90 |
DisclosureSEC source: 0001628280-22-026414 · wf-form4_166577869073110.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 342,903 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.62 to $38.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:18 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,700 | $36.74 | $62,458.00 |
DisclosureSEC source: 0001628280-22-026414 · wf-form4_166577869073110.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 343,533 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 20:18 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 400 | $38.79 | $15,516.00 |
DisclosureSEC source: 0001628280-22-026414 · wf-form4_166577869073110.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 345,233 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.74 to $38.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 20:18 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,217 | $38.35 | $238,421.95 |
DisclosureSEC source: 0001628280-22-026414 · wf-form4_166577869073110.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 345,633 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 to $38.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:44 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 526 | $38.64 | $20,324.64 |
DisclosureSEC source: 0001628280-22-025809 · wf-form4_166457064412784.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 351,850 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:44 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,092 | $38.09 | $232,044.28 |
DisclosureSEC source: 0001628280-22-025809 · wf-form4_166457064412784.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 352,376 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $38.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:44 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 4,718 | $39.07 | $184,332.26 |
DisclosureSEC source: 0001628280-22-025809 · wf-form4_166457064412784.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 358,468 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:44 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 1,900 | $38.54 | $73,226.00 |
DisclosureSEC source: 0001628280-22-025809 · wf-form4_166457064412784.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 363,186 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.745, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 20:12 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 900 | $43.58 | $39,222.00 |
DisclosureSEC source: 0001628280-22-025072 · wf-form4_166335916222767.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 365,086 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 20:12 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 5,718 | $42.41 | $242,500.38 |
DisclosureSEC source: 0001628280-22-025072 · wf-form4_166335916222767.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 365,986 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.95 to $42.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:12 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 6,618 | $41.71 | $276,036.78 |
DisclosureSEC source: 0001628280-22-025072 · wf-form4_166335916222767.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 371,704 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.24 to $42.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:22 UTC | Progyny, Inc. PGNY · Entity 4521 | SaleCommon Stock | 200 | $39.55 | $7,910.00 |
DisclosureSEC source: 0001628280-22-024279 · wf-form4_166215014855277.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 378,322 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 9, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.51 to $39.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.